Compare Capital One Financial Corp. (COF) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Capital One Financial Corp. vs State Street SPDR S&P Biotech ETF — how do they compare? Capital One Financial Corp. trades at $219.76 (market cap $134.45B), while State Street SPDR S&P Biotech ETF trades at $159.47. The key difference: Capital One Financial Corp. pays a 1.46% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Capital One Financial Corp. nearer its low. Which is the better fit depends on your goals.
| COF | XBI | |
|---|---|---|
Market Cap | $134.45B | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $257.94 | $164.28 |
52-Week Low | $176.10 | $86.92 |
Dividend Yield | 1.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Capital One Financial (COF) trades at $218.97, up 0.56% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $251.60. Recent Q2 2026 earnings beat expectations with EPS of $5.81, while revenue growth accelerated to $53.43B in 2025. The Discover integration is on track, targeting $2.5B in synergies by late 2027, supporting double-digit EPS growth projections.
The outlook is positive, driven by strong card growth, technology advantages, and merger synergies, but risks include integration execution, credit loss provisions, and macroeconomic sensitivity. With a P/E of 12.07 and 63% analyst buy ratings, the stock offers value if Discover benefits materialize as planned.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Capital One Financial Corp.
Capital One is a diversified financial services holding company headquartered in McLean, Virginia. Originally a spinoff of Signet Financial's credit card division in 1994, the company is now primarily involved in credit card lending, auto loans, and commercial lending.
Read more on COF →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
